116 related articles for article (PubMed ID: 35723593)
1. Ocular delivery of sunitinib-loaded nanoparticles doped in tragacanthic acid hydrogel in treatment of diabetic retinopathy in rats.
Pirmardvand Chegini S; Varshosaz J; Dehghani A; Minaiyan M; Mirmohammad Sadeghi H
Drug Dev Ind Pharm; 2022 Jan; 48(1):29-39. PubMed ID: 35723593
[TBL] [Abstract][Full Text] [Related]
2. Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy.
Zeng L; Ma W; Shi L; Chen X; Wu R; Zhang Y; Chen H; Chen H
Int J Nanomedicine; 2019; 14():6357-6369. PubMed ID: 31496691
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effect of insulin-loaded chitosan nanoparticles/PLGA-PEG-PLGA hydrogel on diabetic retinopathy in rats.
Rong X; Ji Y; Zhu X; Yang J; Qian D; Mo X; Lu Y
Int J Nanomedicine; 2019; 14():45-55. PubMed ID: 30587984
[TBL] [Abstract][Full Text] [Related]
4. Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats.
Ma J; Zhu T; Tang X; Ye P; Zhang Z
Clin Exp Ophthalmol; 2010 Dec; 38(9):875-84. PubMed ID: 20653693
[TBL] [Abstract][Full Text] [Related]
5. Chitosan coated nanoparticles for efficient delivery of bevacizumab in the posterior ocular tissues via subconjunctival administration.
Pandit J; Sultana Y; Aqil M
Carbohydr Polym; 2021 Sep; 267():118217. PubMed ID: 34119171
[TBL] [Abstract][Full Text] [Related]
6. AMA0428, A Potent Rock Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy.
Hollanders K; Hove IV; Sergeys J; Bergen TV; Lefevere E; Kindt N; Castermans K; Vandewalle E; van Pelt J; Moons L; Stalmans I
Curr Eye Res; 2017 Feb; 42(2):260-272. PubMed ID: 27399806
[TBL] [Abstract][Full Text] [Related]
7. The effect of total lignans from Fructus Arctii on Streptozotocin-induced diabetic retinopathy in Wistar rats.
Zhang H; Gao Y; Zhang J; Wang K; Jin T; Wang H; Ruan K; Wu F; Xu Z
J Ethnopharmacol; 2020 Jun; 255():112773. PubMed ID: 32199990
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.
Wang J; Tan J; Luo J; Huang P; Zhou W; Chen L; Long L; Zhang LM; Zhu B; Yang L; Deng DY
J Nanobiotechnology; 2017 Mar; 15(1):18. PubMed ID: 28249594
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Bevacizumab Injection Attenuates Diabetic Retinopathy in Adult Rats with Experimentally Induced Diabetes in the Early Stage.
Lv J; Chen MM; Mu ZH; Wang F; Qian ZY; Zhou L; Guo QT; Zhao ZM; Pan YP; Liao XY; Yang ZH; Cai N; Li SD; Zou YY
J Diabetes Res; 2018; 2018():9216791. PubMed ID: 29977927
[TBL] [Abstract][Full Text] [Related]
10. An endothelin type A receptor antagonist reverses upregulated VEGF and ICAM-1 levels in streptozotocin-induced diabetic rat retina.
Masuzawa K; Goto K; Jesmin S; Maeda S; Miyauchi T; Kaji Y; Oshika T; Hori S
Curr Eye Res; 2006 Jan; 31(1):79-89. PubMed ID: 16421022
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of streptozotocin-induced diabetic retinopathy with low molecular weight fucoidan via inhibition of vascular endothelial growth factor.
Yang W; Yu X; Zhang Q; Lu Q; Wang J; Cui W; Zheng Y; Wang X; Luo D
Exp Eye Res; 2013 Oct; 115():96-105. PubMed ID: 23810809
[TBL] [Abstract][Full Text] [Related]
12. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina.
Masuzawa K; Jesmin S; Maeda S; Zaedi S; Shimojo N; Miyauchi T; Goto K
Exp Biol Med (Maywood); 2006 Jun; 231(6):1090-4. PubMed ID: 16741055
[TBL] [Abstract][Full Text] [Related]
13. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA‑126 suppresses the proliferation and migration of endothelial cells in experimental diabetic retinopathy by targeting polo‑like kinase 4.
Zheng Y; Liu Y; Wang L; Xu H; Lu Z; Xuan Y; Meng W; Ye L; Fang D; Zhou Y; Ke K; Liu Y; An M
Int J Mol Med; 2021 Jan; 47(1):151-160. PubMed ID: 33416109
[TBL] [Abstract][Full Text] [Related]
15. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of a novel drug RC28-E blocking both VEGF and FGF2 on early diabetic rat retina.
Yang QH; Zhang Y; Jiang J; Wu MM; Han Q; Bo QY; Yu GW; Ru YS; Liu X; Huang M; Wang L; Zhang XM; Fang JM; Li XR
Int J Ophthalmol; 2018; 11(6):935-944. PubMed ID: 29977804
[TBL] [Abstract][Full Text] [Related]
17. Dickkopf-1 exerts protective effects by inhibiting PANoptosis and retinal neovascularization in diabetic retinopathy.
Xu X; Lan X; Fu S; Zhang Q; Gui F; Jin Q; Xie L; Xiong Y
Biochem Biophys Res Commun; 2022 Aug; 617(Pt 2):69-76. PubMed ID: 35691117
[TBL] [Abstract][Full Text] [Related]
18. Poly(glycerol sebacate) nanoparticles for ocular delivery of sunitinib: physicochemical, cytotoxic and allergic studies.
Chegini SP; Varshosaz J; Sadeghi HM; Dehghani A; Minayian M
IET Nanobiotechnol; 2019 Dec; 13(9):974-982. PubMed ID: 31811769
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-15b Targets VEGF and Inhibits Angiogenesis in Proliferative Diabetic Retinopathy.
Yang Y; Liu Y; Li Y; Chen Z; Xiong Y; Zhou T; Tao W; Xu F; Yang H; Ylä-Herttuala S; Chaurasia SS; Adam WC; Yang K
J Clin Endocrinol Metab; 2020 Nov; 105(11):3404-15. PubMed ID: 32797181
[TBL] [Abstract][Full Text] [Related]
20. Repression of microRNA-21 inhibits retinal vascular endothelial cell growth and angiogenesis via PTEN dependent-PI3K/Akt/VEGF signaling pathway in diabetic retinopathy.
Lu JM; Zhang ZZ; Ma X; Fang SF; Qin XH
Exp Eye Res; 2020 Jan; 190():107886. PubMed ID: 31759996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
